Otonomy Inc. is tackling a group of underserved middle and inner ear disorders with a platform of known drugs incorporated into a slow-release polymer gel that could replace multiple injections through the eardrum or weeks of chasing toddlers with an ear dropper with one visit to the ear, nose and throat specialist.
The San Diego biopharma launched two identical Phase III trials in December testing lead product OTO-201, a sustained exposure formulation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?